Global Patent Index - EP 2825989 A4

EP 2825989 A4 20160106 - METHODS OF DISTRIBUTING COMPLEMENT-INHIBITING DRUGS TO PATIENTS RECEIVING A COMPLEMENT INHIBITOR

Title (en)

METHODS OF DISTRIBUTING COMPLEMENT-INHIBITING DRUGS TO PATIENTS RECEIVING A COMPLEMENT INHIBITOR

Title (de)

VERFAHREN ZUR VERTEILUNG VON KOMPLEMENTHEMMENDEN MEDIKAMENTEN AN KOMPLEMENTHEMMER EMPFANGENDE PATIENTEN

Title (fr)

MÉTHODES DE DISTRIBUTION DE MÉDICAMENTS INHIBANT LE COMPLÉMENT AUX PATIENTS RECEVANT UN INHIBITEUR DE COMPLÉMENT

Publication

EP 2825989 A4 20160106 (EN)

Application

EP 12870989 A 20120316

Priority

US 2012029499 W 20120316

Abstract (en)

[origin: WO2013137912A2] This disclosure relates to methods of authorizing distribution of complement-inhibiting drugs to patients who have a complement-associated disorder in a manner to ensure that the patients are aware of the possible dangers of discontinuing treatment with the drugs. A database is prepared comprising patient information including experiencing adverse clinical events after discontinuing the drug treatment. The information in the database is collected and may be reported. The patients are given a warning as to adverse events that may occur if treatment with the complement inhibiting drugs is discontinued.

IPC 8 full level

G06F 19/00 (2011.01); A61K 31/00 (2006.01); C07K 16/18 (2006.01); G01N 33/50 (2006.01); G06F 19/28 (2011.01)

CPC (source: EP)

G01N 33/50 (2013.01); G16H 20/10 (2018.01); G16H 70/40 (2018.01); F04C 2270/041 (2013.01)

Citation (search report)

  • [A] EP 1720571 A2 20061115 - ALEXION PHARMA INC [US]
  • [I] US 2004117126 A1 20040617 - FETTERMAN JEFFREY E [US], et al
  • [I] US 2008097784 A1 20080424 - MILLER SCOTT A [US], et al
  • [Y] WO 2006034367 A2 20060330 - UNIV FLORIDA [US], et al
  • [I] US 6315720 B1 20011113 - WILLIAMS BRUCE A [US], et al
  • [Y] EP 2359834 A1 20110824 - ALEXION PHARMA INC [US]
  • [Y] R. A. BRODSKY ET AL: "Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria", BLOOD, vol. 111, no. 4, 30 November 2007 (2007-11-30), US, pages 1840 - 1847, XP055228630, ISSN: 0006-4971, DOI: 10.1182/blood-2007-06-094136
  • [I] HILL ANITA ET AL: "Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, no. 7, 1 October 2005 (2005-10-01), pages 2559 - 2565, XP002482089, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2005-02-0564
  • [Y] ROTHER R P ET AL: "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, US, vol. 25, no. 11, 12 December 2007 (2007-12-12), pages 1256 - 1264, XP002553743, ISSN: 1087-0156, [retrieved on 20071107], DOI: 10.1038/NBT1344
  • See also references of WO 2013137912A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2013137912 A2 20130919; WO 2013137912 A3 20140501; CN 104205155 A 20141210; EA 201400950 A1 20141230; EP 2825989 A2 20150121; EP 2825989 A4 20160106; HK 1204693 A1 20151127; IL 234680 D0 20141130

DOCDB simple family (application)

US 2012029499 W 20120316; CN 201280071445 A 20120316; EA 201400950 A 20120316; EP 12870989 A 20120316; HK 15105150 A 20150529; IL 23468014 A 20140916